EcoDrugPlus

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSDORG00000005013
Gene Symbol: PIK3R5
4 Cross references
256 Possible Orthologues:

Phospholipase A2 Group Iia

Ensembl ID : ENSDORG00000001096
Gene Symbol: PLA2G2A
2 Cross references
171 Possible Orthologues:

Phospholipase A2 Group V

Ensembl ID : ENSDORG00000015526
Gene Symbol: PLA2G5
3 Cross references
116 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSDORG00000002551
Gene Symbol: PLA2G7
2 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSDORG00000015688
Gene Symbol: PLA2G10
3 Cross references
250 Possible Orthologues:

Phosphoribosylglycinamide Formyltransferase, Phosphoribosylglycinamide Synthetase, Phosphoribosylaminoimidazole Synthetase

Ensembl ID : ENSDORG00000011828
Gene Symbol: GART
3 Cross references
247 Possible Orthologues:

Plasminogen

Ensembl ID : ENSDORG00000024248
Gene Symbol: PLG
3 Cross references
269 Possible Orthologues:

Plasminogen Activator, Tissue Type

Ensembl ID : ENSDORG00000011916
Gene Symbol: PLAT
3 Cross references
203 Possible Orthologues:

Platelet Activating Factor Receptor

Ensembl ID : ENSDORG00000027100
Gene Symbol: PTAFR
4 Cross references
224 Possible Orthologues:

Platelet Derived Growth Factor Receptor Alpha

Ensembl ID : ENSDORG00000002763
Gene Symbol: PDGFRA
4 Cross references
204 Possible Orthologues:

Platelet Derived Growth Factor Receptor Beta

Ensembl ID : ENSDORG00000009895
Gene Symbol: PDGFRB
3 Cross references
247 Possible Orthologues:

Platelet Derived Growth Factor Subunit B

Ensembl ID : ENSDORG00000010253
Gene Symbol: PDGFB
4 Cross references
263 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).